Chris Anzalone, Arrowhead CEO
Takeda, Arrowhead spotlight data from small trial showing RNAi works in a rare liver condition
Almost two years after Takeda wagered $300 million cash to partner with Arrowhead on an RNAi therapy for a rare disease, the companies are spelling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
